SIDE-BY-SIDE EVIDENCE

Compare evidence.
Keep the context.

Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.

Choose profiles

SIDE-BY-SIDE EVIDENCE VIEW

Compare selected profiles

Evidence comparison · not a treatment ranking

Evidence boundaries, not cross-trial treatment outcomes
Molecule	Ovagen (EDL)	Cartalax / AED	Epitalon
Research Topic	Clinical / Endocrine Pharmacology	Tissue / Repair Research	Longevity / Aging Research
Pharmacology	Experimental Glu-Asp-Leu tripeptide; renal cell and animal research	AED tripeptide / T-31 candidate	Experimental synthetic pineal-derived tetrapeptide
PrimeCore Class	Class ENeeds Verification	Class ENeeds Verification	Class CExperimental / limited evidence
Evidence Grade	Grade EPreclinical evidence	Grade EPreclinical evidence	Grade CEarly human evidence
Evidence boundary	Ovagen is linked to the Glu-Asp-Leu (EDL) tripeptide in research-group literature, but that name does not authenticate a supplier product. It must be distinguished from the unrelated ovine FSH preparation also called Ovagen. Verified EDL studies concern renal cell/tissue cultures, rat kidney-injury models and computational DNA docking. Cell biomarkers and animal kidney signals do not establish human liver repair, kidney treatment, anti-aging benefit or administration safety. No randomised human trial of exact EDL was verified in the reviewed sources. Class E denotes unresolved exact-product identity and authorisation; Grade E denotes preclinical evidence. Registration in Thailand, the U.S., EU and UK remains unverified for the supplier product.	This profile reviews AED/T-31 evidence associated with the Cartalax name, without authenticating the supplier product. Skin-fibroblast and rat-kidney culture findings do not establish cartilage regeneration, arthritis treatment or human anti-ageing benefit. AED is distinct from AEDG and AEDP.	An experimental tetrapeptide with limited human evidence; cell or biomarker findings do not establish human lifespan extension.
Unknowns	Insufficient data in the current dataset	Insufficient data in the current dataset	whether human-study material was free base, acetate or another formulation whether biomarker changes produce better sleep or any patient-important outcome efficacy and safety in people with diagnosed insomnia effects on human lifespan, healthspan, cancer risk and long-term organ function human pharmacokinetics, dose-response and route comparability independent replication beyond a concentrated research network current Thailand and Russia regulatory status pending direct official verification
Limitations	English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) หลักฐานที่ทบทวนเป็น preclinical และใช้สารหรือแบบจำลองที่ระบุ ไม่พบการทดลองมนุษย์แบบสุ่มของ exact EDL ที่ตรวจยืนยันได้จากแหล่งเหล่านี้ การเชื่อมชื่อ Ovagen–EDL ในตารางวิจัยไม่ใช่การรับรองผลิตภัณฑ์ และคำว่า hepatoprotection ในบททบทวนไม่แทนผลลัพธ์ผู้ป่วยตับ ห้ามนำงาน Ovagen/FSH ในสัตว์มาอ้างเป็นหลักฐานของ EDL	English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) ชื่อ Cartalax ไม่ทำให้หลักฐานในไตหรือ fibroblast กลายเป็น clinical cartilage-regeneration evidence	The available human evidence is biomarker-focused, short-term and does not evaluate insomnia or longevity outcomes. Much of the broader literature comes from related investigators and mixes Epitalon with Epithalamin, a different pineal extract. Cell, mouse and primate findings cannot be merged into a human efficacy claim. FDA found no clinical safety studies and no evidence supporting insomnia treatment.
Sources	2022 research-group paper · Table 2 identifies Ovagen (EDL); modelling/review, not a human efficacy trial PMID 18325004 · Ovagen as ovine FSH in porcine oocyte culture — a different substance PMID 8265802 · Veterinary FSH preparations sharing the Ovagen name Renal cell ageing · PMID 25946838 (2014) Kidney tissue renewal · PMID 26033601 (2015) Cisplatin kidney-injury model · PMID 26515176 (2015) Acute kidney injury models · PMID 28744634 (2017) DNA docking hypothesis · PMID 27909961 (2016)	Author-group review · Cartalax/AED name mapping only, not clinical efficacy Skin fibroblasts · PMID 27259496 Kidney explants · PMID 26033601	https://www.fda.gov/media/193345/download https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://pubmed.ncbi.nlm.nih.gov/33280326/ https://pubmed.ncbi.nlm.nih.gov/12937682/ https://pubmed.ncbi.nlm.nih.gov/14501183/ https://pubmed.ncbi.nlm.nih.gov/29124531/ https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list https://products.mhra.gov.uk/
Read more	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)

This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.

Choose another comparison

Continue reading

Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.

10 questions before drawing conclusions

Compare evidence.Keep the context.

Continue reading

Contact PrimeCoreBio

Compare evidence.
Keep the context.